For the year ending 2025-12-31, RCUS made $247M in revenue. -$353M in net income. Net profit margin of -142.91%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenues | 247 | - | ||
| Research and development (includes 25, (39) and (110) payments to/(from) a related party) | 523 | - | ||
| General and administrative (includes 5, 2 and payments to a related party) | 110 | - | ||
| Impairment of long-lived assets (see note 14, leases) | 0 | - | ||
| Total operating expenses | 633 | - | ||
| Loss from operations | -386 | -330 | ||
| Interest and other income, net | 41 | 52 | ||
| Interest expense | 8 | 4 | ||
| Total non-operating income, net | 33 | 48 | ||
| Loss before income taxes | -353 | -282 | ||
| Federal statutory income taxes | 74 | - | ||
| State taxes, net of federal benefit | 0 | - | ||
| Domestic research and development credits | -15 | - | ||
| Equity investment | 12 | - | ||
| Stock based compensation | -4 | - | ||
| Other items | -5 | - | ||
| Change in valuation allowance | -92 | - | ||
| Income tax expense | 0 | 1 | ||
| Net loss | -353 | -283 | ||
| Basic EPS | -3.29 | -3.14 | ||
| Diluted EPS | -3.29 | -3.14 | ||
| Basic Average Shares | 107,400,000 | 90,100,000 | ||
| Diluted Average Shares | 107,400,000 | 90,100,000 | ||
Arcus Biosciences, Inc. (RCUS)
Arcus Biosciences, Inc. (RCUS)